Trio Resources Inc (TRII): We will be fine. Will be hard to...

esi23 · 2025-01-30T13:36:58.6270000Z

We will be fine. Will be hard to build a position soon. When the masses find us we will fly to multi Pennie's to start.

Play Episode

4min

Proactive - Interviews for investors

Charbone Hydrogen partners with ABB to develop 15 green hydrogen facilities in North America

Charbone Hydrogen Chief Operations Officer Daniel Charette joined Steve Darling from Proactive to announce the signing of a Memorandum of Understanding with ABB, marking a significant step toward scaling green hydrogen production across North America. The agreement outlines plans to develop up to 15 modular and scalable hydrogen production facilities over the next five years, targeting industries that currently rely on grey hydrogen, such as steelmaking and heavy industrial processes. Under the MoU, ABB will serve as Charbone’s preferred supplier for modular electrical substations (eHouses), providing design, engineering, fabrication, and testing. ABB will also assist in standardizing core engineering systems across Charbone’s project portfolio to enhance energy efficiency and reliability. Depending on project needs, ABB may also take on automation, electrification, and telecom roles. One of the first projects in this collaboration is Charbone’s flagship Sorel-Tracy facility, located near Montreal, Québec. Expected to be connected to the Hydro-Québec grid by Q2 2025, the facility will utilize hydroelectric power to run green hydrogen electrolyzers, creating a scalable model for future sites. Following this, Charbone’s next project will be in the greater Detroit area, a key hub for automotive manufacturing. This initiative aligns with the Government of Québec’s Green Hydrogen and Bioenergy Strategy, which aims to reduce petroleum consumption by nearly 1 billion liters annually by 2030. By promoting green hydrogen adoption in key industrial sectors, the province could cut greenhouse gas emissions by 4 megatons of CO₂ per year—equivalent to removing 1.2 million gasoline-powered vehicles from the roads. With its partnership with ABB and government-backed initiatives supporting clean energy, Charbone Hydrogen is positioning itself as a leader in North America’s transition to sustainable hydrogen solutions. #proactiveinvestors #charbonehydrogencorportion #tsxv #ch #ot

Proactive - Interviews for investors

Graphene Manufacturing Group advances aluminium-ion battery development with key U.S. partnership

Graphene Manufacturing Group CEO Craig Nicol joined Steve Darling from Proactive to share an update as the company continues to make strides in the development of its Graphene Aluminium-Ion Battery technology, a cutting-edge innovation being pursued in collaboration with the University of Queensland and Rio Tinto under a Joint Development Agreement. Nicol told Proactive, to accelerate battery development, GMG has signed a service contract with the Battery Innovation Center (BIC) in Indiana, USA. This partnership will support the next phase of research and optimization, leveraging BIC’s state-of-the-art 40,000-square-foot facility in Newberry, Indiana. As a globally recognized innovation hub, BIC specializes in advancing battery technologies, offering end-to-end support from research and development to prototype manufacturing and low-volume production—a critical advantage for GMG as it scales up its graphene-based energy storage solutions. Nicol emphasized that collaborating with BIC allows GMG to access advanced battery manufacturing infrastructure without incurring the high capital costs of building its own pilot production facility—an investment that could exceed AU$10 million. Through this agreement, GMG will retain full intellectual property (IP) rights over the battery development work, ensuring control over its proprietary technology while optimizing BIC’s cell design expertise and battery manufacturing capabilities. By integrating BIC’s expertise into its scale-up strategy, GMG can streamline the production of sample battery cells before committing to mass production, reducing risks and deferring large capital expenditures until the technology reaches a higher level of readiness. Looking ahead, GMG aims to optimize battery performance, produce initial test cells this year, and engage customers for validation. Nicol noted strong interest from major companies eager to integrate this technology. #proactiveinvestors #graphenemanufacturinggroupltd #BatteryTech #

Proactive - Interviews for investors

Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Followers	90
Posts	8419
Boards Moderated	0
Alias Born	07/26/2006

Volume:	13,500
Day Range:	0.0022 - 0.0025
Bid:	0.0012
Ask:	0.0025
Last Trade Time:	2:37:31 PM EDT
Total Trades:	4

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

TRII Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free